Roy Baynes has served as a member of our board of directors since July 2018. Dr. Baynes is Chief Medical Officer at Merck, and Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories. Dr. Baynes was previously Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at Gilead Sciences, and also served as Vice President of Global Clinical Development and Therapeutic Area Head for Hematology/Oncology at Amgen. Dr. Baynes has had a long and distinguished career in the hematology, oncology, and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching, and administration. He is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research, and has authored about 150 publications. Before joining industry in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center. Dr. Baynes graduated as a medical doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand in Johannesburg, South Africa.

Roelof F. Botha has served as a member of our board of directors since 2007. Mr. Botha has been with Sequoia Capital, a venture capital firm, since 2003, and has been a Managing Member of Sequoia Capital Operations, LLC since 2007.From 2000 to 2003, Mr. Botha served in a number of roles at PayPal, Inc., most recently as the Chief Financial Officer. From 1996 to 1998, Mr. Botha served as a management consultant for McKinsey & Company, a management consulting firm. Mr. Botha currently serves on the board of directors of Square, Inc. (NYSE: SQ), a provider of payments, financial and marketing services; MongoDB, Inc. (Nasdaq: MDB), a document oriented database program developer; Eventbrite, Inc. (NYSE: EB), an event management and ticketing platform; Unity, Inc. (NYSE: U), a 3D and VR content development platform, and a number of private companies. Mr. Botha holds a Bachelor of Science in Actuarial Science, Economics, and Statistics from the University of Cape Town and an M.B.A. from Stanford University.

Rowan Chapman has served as a member of our board of directors since August 2019. Dr. Chapman is a founder, investor, and active independent board member of various companies. She most recently held senior roles as Head of Johnson & Johnson Innovation, Western North America, Australia and New Zealand, and as Head of Precision Diagnostics at GE Healthcare Life Sciences, Managing Director of New Business Creation, and Head of Healthcare Investing at GE Ventures. Prior to that, she held operational roles in early and growth-stage startups and was a partner at Mohr Davidow Ventures for over 11 years, gaining extensive experience as a board member and board advisor for a wide variety of tech and data-enabled companies. Dr. Chapman holds a Bachelor of Arts degree in Biochemistry and a Doctor of Philosophy degree in Biochemistry and Molecular Biology from the University of Cambridge, United Kingdom.

Steve Chapman is Natera’s Chief Executive Officer and serves on the company’s board of directors. Mr. Chapman joined Natera in 2010 as Vice President of Sales, later becoming Chief Commercial Officer and then Chief Operating Officer. As COO, he led the company’s commercial entry into the highly competitive non-invasive prenatal testing market, in which the company’s Panorama® test became the market leader despite being fourth to market. Mr. Chapman was appointed CEO in January 2019 and has been instrumental in extending Natera’s core technology to address new organ health and oncology markets, achieving rapid commercial growth for the Prospera™ transplant assessment test and establishing Natera’s leadership in molecular residual disease testing with Signatera.™ Since becoming CEO, Natera has achieved year-on-year revenue growth of over 40% and has consistently outperformed earnings expectations. Prior to joining Natera, Mr. Chapman worked at Genzyme Genetics, where he was credited with delivering record-breaking commercial growth and strategies that changed pregnancy genetic testing. Mr. Chapman began his career as a researcher in the department of human genetics at UCLA designing arrays identifying SNPs associated with multiple sclerosis. He graduated with honors and holds a BS in Microbiology, Immunology, and Molecular Genetics from UCLA.

James I. Healy has served as a member of our board of directors since November 2014. Dr. Healy has been a General Partner at Sofinnova Ventures, a venture capital firm, since 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, a venture capital firm, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories), a research-based pharmaceutical company and ISTA Pharmaceuticals, Inc., a company specializing in ophthalmic pharmaceutical products. Dr. Healy is currently the Chairman of CinCor (CINC) and of Y-mAbs (YMAB), a member of the board of directors for Atsena, Karuna (KRTX), the lead independent director of Bolt (BOLT) and a board observer at Visen. Previously, Dr. Healy served as a board member of Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammation and autoimmune diseases, from 2006 to 2014; Durata Therapeutics, Inc., a pharmaceutical company focused on infectious and acute diseases, from 2009 to 2013; InterMune, Inc., a biotechnology company focused on orphan fibrotic pulmonary disease, from 1999 to 2014; KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of monoclonal antibody therapeutics, from 2001 to 2014; Hyperion Therapeutics, Inc., a commercial-stage orphan disease company, from 2007 to 2015 and several private companies. Dr. Healy holds an M.D. and Ph.D. in Immunology from Stanford University School of Medicine and performed neuroscience research at the University of Virginia School of Medicine. Dr. Healy holds a Bachelors of Arts in Molecular Biology and Scandinavian Studies from the University of California at Berkeley.

Gail Marcus has served as a member of our board of directors since March 2017. Dr. Marcus is currently an Assistant Professor and Executive in Residence at the Massachusetts College of Pharmacy and Health Sciences. Prior to academia, Dr. Marcus was a healthcare executive across a diverse portfolio of healthcare organizations in the US and UK, including Cigna, UnitedHealthcare Group Inc., CVS/Caremark, and Caris Diagnostics of Caris Life Sciences. In 2014, she was selected as one of the top 100 women executives in Massachusetts. Dr. Marcus currently serves on the boards of directors of another public company, a private company and a non-profit organization, and sits on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests. Dr. Marcus holds a Doctorate of Health Administration from the Medical University of South Carolina. She received a B.A. in Spanish and Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School Of Engineering and a M.B.A. from the Wharton School of the University of Pennsylvania.

Dr. Matthew Rabinowitz is co-founder of Natera and currently serves as the Executive Chairman of the board of directors. He served as Natera’s Chief Executive Officer from 2005 to 2018. Prior to co-founding Natera, Dr. Rabinowitz founded Rosum Corporation, a location-systems company that used terrestrial digital television broadcasts to enhance GPS indoors, where he was Chief Executive Officer from 2000 to 2003 and Chief Technology Officer from 2003 to 2006. For this technology, Dr. Rabinowitz received the Scott Helt Memorial Award from the IEEE. From 1998 to 2000, he served as co-founder and Chief Scientist of Inc., a technology company for personalized online merchandising that was sold after roughly two years for $100M. Dr. Rabinowitz served as a consulting professor at Stanford University for 8 years and in 2018, began as Visiting Faculty in the Genetics Department of Harvard University. He has served as Principal Investigator on six research grants from the National Institutes of Health and has authored over 100 patents and academic papers, including journals such as IEEE Transactions, Bioinformatics, Science, Nature, JAMA Oncology, Journal of Clinical Oncology, Human Reproduction, Molecular Human Reproduction, Fertility and Sterility, Obstetrics and Gynecology, Ultrasound in Obstetrics and Gynecology, and Genome Medicine. Two companies that he founded received the World Economic Forum Technology Pioneer award, awarded each year to 20 companies worldwide. He is on the board of the foundation of the American College of Medical Genetics and is a board member, advisor, and angel investor for multiple companies in biotechnology, diagnostics, gene editing, machine learning, communications, and cleantech. Dr. Rabinowitz completed one year at the University of the Witwatersrand, South Africa, and holds a Bachelor of Science degree in Physics, a Master of Science in Electrical Engineering, and a Ph.D. in Electrical Engineering with a minor in Aeronautics and Astronautics, all from Stanford University.

Herm Rosenman served as our Chief Financial Officer from February 2014 to January 2017, and has served as a member of our board of directors since February 2017. Prior to joining our company, he held the position of Senior Vice President—Finance and Chief Financial Officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood, from June 2001 to April 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Prior to joining Gen-Probe, he was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. Mr. Rosenman has served on the board of directors of Oxford Immunotec Global PLC, a commercial stage diagnostics company, since2013. Mr. Rosenman served on the board of directors of Medistem, Inc., a stem cell therapy company, from 2013 to2014; ARYx Therapeutics Inc., a private drug discovery and development company, from 2006 to 2009; Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chairman of the Audit Committee, from 2003 to 2007. He has also served on the board of directors of a number of privately held companies. Mr. Rosenman holds a B.B.A. in accounting and finance from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.

Jonathan Sheena is a co-founder of our company. Mr. Sheena has served as a member of our board of directors since 2007, and served as our Chief Technology Officer from 2007 to December 2020. In 1999, Mr. Sheena co-founded PhoneSpots, Inc. (formerly PocketThis, Inc.), a mobile technology company serving mobile carriers worldwide. From June1999 to December 2007, Mr. Sheena held various roles at PhoneSpots, Inc. including vice president of product management and chief technology officer. Mr. Sheena holds a Bachelor of Science in Electrical Engineering and Computer Science, and a Master of Engineering in Electrical Engineering and Computer Science, from the Massachusetts Institute of Technology.